Why Recursion Pharmaceuticals Stock Is Up Today

Source The Motley Fool

Key Points

  • One of Recursion Pharmaceuticals’ internally developed drugs is advancing to late-stage clinical trials.

  • While only aiming at a relatively small opportunity, Wednesday’s announcement affirms the value of Recursion’s AI-powered pre-clinical-testing solution.

  • Just recognize that today’s seemingly volatile action isn’t unusual, and may largely be fueled by the stock’s recent extreme weakness.

  • 10 stocks we like better than Recursion Pharmaceuticals ›

Shares of pharmaceutical-development platform developer Recursion Pharmaceuticals (NASDAQ:RXRX) are soaring today in response to regulatory progress from one of its own drugs. Specifically, as of 11:59 a.m. ET this drug-design-technology name's stock is up by 5.4% following this morning's announcement that the U.S. Food and Drug Administration is in agreement with the company's design for Phase 3 trials of its REC-4881 -- an oral MEK1/2 inhibitor that treats familial adenomatous polyposis, or FAP.

While the FAP market is underserved, this step forward means more for the company than just developmental progress of one drug for the treatment of one illness. Just don't lose perspective on the matter.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

A reminder of its technological platform's potential

It's often categorized as a drug company, but that description doesn't quite do Recursion Pharmaceuticals justice. The company has developed an artificial intelligence platform capable of virtually pre-testing a potential drug molecule before time and money are spent on an actual clinical trial.

Glowing upward-trending arrow over a digital world map on a dark blue background.

Image source: Getty Images.

A handful of major pharmaceutical outfits including Sanofi and Roche are partnering with Recursion in exchange for access to this platform too, but REC-4881 is one of Recursion Pharmaceuticals' own drugs. It's also now easily the one furthest along the developmental pipeline, with Phase 3 testing expected to begin in the latter half of next year.

While FAP is relatively rare, today's announcement reminds investors that Recursion's virtualized drug-development platform can lay the groundwork for the eventual creation of a very real drug. That's a big part of what's driving RXRX higher on Wednesday.

Neither unusual nor surprising

Just don't read too much into the bullish move. This ticker was already ripe for a sizable bounce, by virtue of tumbling more than 40% between its late-October peak and yesterday's new 52-week low. Also know that while today's news is clearly positive and the stock's gain is compelling, such single-day gains (or losses) aren't unusual for this volatile ticker.

The FDA's nod comes as no significant surprise either. Even if it required regulatory modifications, REC-4881's Phase 3 trial was bound to materialize at some point in the foreseeable future.

There's speculative potential upside here to be sure. Wednesday's announcement and move, though, don't actually bolster the bullish argument a great deal.

Should you buy stock in Recursion Pharmaceuticals right now?

Before you buy stock in Recursion Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $321,850!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $955,232!*

Now, it’s worth noting Stock Advisor’s total average return is 793% — a market-crushing outperformance compared to 203% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 18, 2026.

James Brumley has no position in any of the stocks mentioned. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
US Dollar Index Price Forecast: DXY could target 104.00 as bulls await FOMC MinutesThe US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
Author  FXStreet
7 hours ago
The US Dollar Index (DXY), which tracks the Greenback against a basket of currencies, regains positive traction following the previous day's brief pause, retesting its highest level since April 2025 during the first half of the European session on Wednesday.
placeholder
Gold Hits Near 1.5-Year Low Below $3,800 as Bears Threaten Drop to $3,500Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
Author  TradingKey
9 hours ago
Gold prices broke below the $3,800 threshold to hit a new low since September 2025, warranting heightened vigilance over downside risk toward $3,500.On November 18, international spot gol
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 18, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
Author  Mitrade
14 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 18, 2026. Read on for the details.
placeholder
Nvidia posts record $115.8B Q3 revenue, but crypto stays mutedThe crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
Author  FXStreet
16 hours ago
The crypto market remained subdued on Tuesday despite Nvidia's (NVDA) Q3 earnings release beating analysts' expectations as demand for artificial intelligence infrastructure continued to drive growth across its business.
placeholder
Nvidia Q3 Earnings Loom as Market Expects Revenue Near $109 Billion: Can NVDA Stock Hold $150? As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
Author  TradingKey
Yesterday 09: 10
As of the close on November 16 ET, Nvidia (NVDA) shares fell 4.12% to close at $156.14, with an intraday low of $155.01 and trading volume of about 334 million shares. Compared with its p
goTop
quote